HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watts, R. L. Search for Related Content PubMed PubMed Citation Articles by Watts, R. L.

The role of dopamine agonists in early Parkinson's disease

From the Department of Neurology, Emory University School of Medicine, Atlanta, GA.

Address correspondence and reprint requests to Dr. Ray L. Watts, Department of Neurology, Emory University School of Medicine, 6000 WMRB, P.O. Drawer V, Atlanta, GA 30322.

Abstract.

Recent evidence from clinical studies suggests an expanded role for dopamine agonists as initial dopaminergic monotherapy in the treatment of Parkinson's disease (PD). The rationale for the use of dopamine agonist monotherapy in early disease is to delay the initiation of levodopa or to decrease the total exposure to levodopa, thereby reducing the motor complications of long-term levodopa therapy. Dopamine agonists, when used alone, rarely promote the development of dyskinesias and motor fluctuations that complicate levodopa treatment. Theoretically, there is potential for a neuroprotective effect by decreasing the oxidative breakdown of dopamine and free radical generation. Because they act on postsynaptic dopamine receptors of the striatum, dopamine agonists act independent of the synthetic dopaminergic enzyme system and are not dependent on degenerating presynaptic neurons in the substantia nigra. This article will review the traditional role of dopamine agonists and will focus on emerging strategies for the treatment of PD, including early monotherapy with dopamine agonists and early combination therapy with dopamine agonists and levodopa.

This article has been cited by other articles:

				M. Nakagawa, M. Ohgoh, Y. Nishizawa, and H. Ogura Dopaminergic Agonists and Muscarinic Antagonists Improve Lateralization in Hemiparkinsonian Rats in a Novel Exploratory Y-Maze J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 737 - 744. [Abstract] [Full Text] [PDF]

				A.H. V. Schapira Disease-modifying strategies and challenges in PD: Interactive breakout sessions Neurology, September 23, 2003; 61(90063): S56 - 63. [Full Text]

				J. C. Chappell and H. Cohen Frontiers in Neuropharmacotherapy Part II: Multiple Sclerosis and Parkinson's Disease Journal of Pharmacy Practice, June 1, 2002; 15(3): 221 - 240. [Abstract] [PDF]